Skip to content
ContentLora

    Tip: press / anywhere to search.

    ● Developing story

    Cancer screening and prevention tracker: 2026 guidelines, trials, FDA

    This tracker logs 2026 developments in cancer screening and prevention. As of 11 October 2026 the main open question is whether the FDA will approve Galleri, the first multi-cancer blood test to reach an advisory panel, which voted in its favour on 23 September.[1][2] Other 2026 milestones include self-collected HPV testing entering US cervical guidelines, a second FDA-approved colorectal blood test, and targeted prostate screening in the UK.[3][4][5]

    Editor reviewedStrict sourcingUpdated DevelopingHealth and medicine, Tech policy, Life sciences

    What we know

    • NHS-Galleri missed its primary endpoint (stage III–IV) but found 14% fewer stage IV cancers.[7]
    • An FDA advisory panel voted 7-2 (one abstention) that Galleri's benefits outweigh its risks (23 Sept 2026).[1]
    • Galleri was not FDA-cleared or approved as of 11 October 2026.[2]
    • The FDA approved a second colorectal screening blood test, SimpleScreen CRC, on 27 July 2026.[4]
    • The ACS (January 2026) accepts self-collected HPV samples for cervical screening at ages 25–65.[3]
    • The UK NSC recommended PSA screening only for men 45–61 with a BRCA2 variant and family history (May 2026).[5]
    • The USPSTF had not met for more than a year as of September 2026.[11]

    What we don't know yet

    • Whether and when the FDA approves Galleri, and on what label.
    • Whether NHS-Galleri's stage IV reduction holds with longer follow-up and translates into fewer cancer deaths.
    • When the reconstituted USPSTF will meet, and whether it will finalise its pending cervical and prostate updates.
    • Whether USPSTF will add blood-based colorectal tests to its recommendation.
    • Whether Scotland, Wales and Northern Ireland adopt the UK NSC's targeted prostate screening recommendation.
    Story status

    Story status

    State
    developing
    Started
    2026-01-01
    Timeline entries
    15
    Last entry

    Timeline data (JSON)

    This tracker follows cancer screening and prevention news in 2026: guideline changes, trial results and regulatory decisions. Entries are dated and cited, and the newest appear first in the timeline. For background, start with the cancer screening explainer. Treatment news, including immunotherapy approvals, is covered by the separate cancer immunotherapy tracker.

    This page is not medical advice. Talk to a clinician about your own screening and prevention.

    Multi-cancer blood tests

    The biggest screening story of 2026 is Galleri. In May, GRAIL presented full results of NHS-Galleri, the first randomised MCED trial. It did not reduce combined stage III and IV cancers but found 14% fewer stage IV cancers, a secondary endpoint.[6][7] Some experts said the results were presented more positively than they justify.[8] The full papers appeared in NEJM and Nature Medicine on 22 September.[9] The next day, an FDA advisory panel voted in Galleri’s favour.[1] As of 11 October the FDA had not decided.[2] See the multi-cancer early detection analysis for the competing views.

    Guideline changes

    • Cervical: the American Cancer Society accepted self-collected HPV samples in January, and ACOG endorsed HRSA guidelines with the same option in April.[3][10]
    • Prostate (UK): the UK NSC recommended against population PSA screening and for targeted screening of a small BRCA2 group.[5]
    • USPSTF: no new cancer recommendations. The task force had not met for more than a year, lost its two leaders in May and gained eight new members in September.[11][12][13]

    New tests

    The FDA approved Freenome’s SimpleScreen CRC, a second blood test for colorectal screening, on 27 July 2026. Abbott will market it.[4] Its published accuracy is compared with stool tests and Shield in our buyer’s guide.

    Prevention research

    A February 2026 Nature Medicine analysis attributed 37.8% of new cancers worldwide to modifiable risk factors, led by smoking, infections and alcohol.[14] The American Cancer Society reported that US colorectal cancer incidence is rising by 3% a year in adults aged 20 to 49.[15] More is in cancer prevention explained.

    Timeline

    15 confirmed

    1. confirmed

      Galleri still not FDA-approved; decision pending[2]

    2. confirmed

      UK NSC restates that surrogate outcomes cannot yet replace cancer deaths as the measure of screening benefit[22]

    3. confirmed

      FDA advisory panel votes in favour of Galleri (7-2 on benefit-risk, 6-4 on effectiveness)[1]

    4. confirmed

      NHS-Galleri published in NEJM and Nature Medicine; PATHFINDER 2 in Nature Medicine[9][20][21]

    5. confirmed

      Kennedy names eight new USPSTF members, with Seth Corey as chair[13][11]

    6. confirmed

      FDA approves Freenome's SimpleScreen CRC blood test; Abbott to market it[4]

    7. confirmed

      NHS-Galleri full results at ASCO; primary endpoint missed, stage IV cancers down 14%[9][6][7][8]

    8. confirmed

      UK NSC recommends targeted prostate screening for BRCA2 carriers with a family history, not population screening[5]

    9. confirmed

      HHS Secretary Kennedy removes the USPSTF's two leaders[12]

    10. confirmed

      ACOG endorses HRSA cervical guidelines adding patient-collected HPV testing[10]

    11. confirmed

      ACS colorectal cancer statistics report finds rising incidence in adults under 50[15]

    12. confirmed

      Nature Medicine study attributes 37.8% of global cancer cases to modifiable risk factors[14]

    13. confirmed

      GRAIL submits FDA premarket approval application for Galleri[18][19]

    14. confirmed

      American Cancer Society updates cervical guideline to accept self-collected HPV samples (January 2026 issue of CA)[3][16]

    15. confirmed

      ACS Cancer statistics, 2026: about 2.11 million new US cases and 626,140 deaths projected[17]

    Developing in Health

    Questions readers ask

    What changed in cancer screening in 2026?

    US cervical guidelines from the ACS and HRSA added self-collected HPV testing, the FDA approved a second colorectal blood test, the UK NSC recommended targeted prostate screening, and the NHS-Galleri multi-cancer trial reported.[3][10][4][5][6]

    When will the FDA decide on Galleri?

    No date has been announced. After the 23 September 2026 panel vote, GRAIL said it expects a final FDA decision in the coming months.[2][1]

    Has the USPSTF changed its cancer screening recommendations in 2026?

    No. Its cervical and prostate updates remain in progress, and the panel had not met for more than a year as of September 2026.[23][24][11]

    Sources

    · 24 claims from 19 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      On 23 September 2026 an FDA advisory panel voted 7-2 with one abstention that Galleri's benefits outweigh its risks, unanimously on safety, and 6-4 on effectiveness, for screening adults aged 50 and older; the FDA is not bound by the vote. confirmedas of 2026-09-23

    2. [2]

      As of 11 October 2026 Galleri's own site stated that the test has not been cleared or approved by the FDA; it is sold as a laboratory-developed test under CLIA and requires a prescription. confirmedas of 2026-10-11

    3. [3]

      The American Cancer Society's January 2026 cervical guideline update accepts self-collected vaginal HPV samples for average-risk people aged 25 to 65 (clinician collection preferred), with repeat testing 3 years after a negative self-collected test. confirmedas of 2026-10-11

    4. [4]

      On 27 July 2026 the FDA approved Freenome's SimpleScreen CRC blood test for average-risk adults 45 and older; in the PREEMPT CRC study it detected 81.1% of colorectal cancers and 13.7% of advanced precancerous lesions, with 90.4% specificity, and Abbott will sell it in the US. A study investigator quoted by Freenome said a blood test offers another way to reach unscreened patients. confirmedas of 2026-07-27

    5. [5]

      In May 2026 the UK NSC recommended targeted prostate screening, with a PSA test every 2 years, for men aged 45 to 61 who carry a harmful BRCA2 variant and have a family history of breast, ovarian, pancreatic or prostate cancer, and recommended against population screening. confirmedas of 2026-05-28

    6. [6]

      NHS-Galleri missed its primary endpoint; the rate of stage III or IV cancer across 12 prespecified cancer types did not differ significantly between groups after three rounds (incidence rate ratio 1.03, 95% CI 0.92 to 1.14). confirmedas of 2026-10-11

    7. [7]

      In NHS-Galleri, the incidence rate ratio for stage IV cancer, a key secondary endpoint, was 0.86 (95% CI 0.74 to 1.00) after three rounds, a 14% reduction that GRAIL described as nominally significant. confirmedas of 2026-10-11

    8. [8]

      Richard Houlston of the Institute of Cancer Research said the NHS-Galleri findings were presented far more positively than the overall results justify, and warned that low early-stage sensitivity and false positives would mean extra scans and biopsies and pressure on stretched NHS diagnostic services; the NEJM authors say further follow-up is warranted. confirmedas of 2026-05-30

    9. [9]

      GRAIL presented full NHS-Galleri results at the ASCO Annual Meeting on 30 May 2026; the main results and performance data were published in NEJM and Nature Medicine on 22 September 2026. confirmedas of 2026-10-11

    10. [10]

      On 23 April 2026 ACOG endorsed updated HRSA Women's Preventive Services guidelines that add patient-collected HPV testing every 3 years as an option at ages 30 to 65, with clinician primary HPV testing every 5 years preferred. confirmedas of 2026-04-23

    11. [11]

      As of September 2026 the USPSTF had not met for more than a year after its meetings were cancelled by HHS Secretary Robert F. Kennedy Jr. confirmedas of 2026-09-17

    12. [12]

      In letters dated 11 May 2026, Kennedy removed the task force's two leaders, John Wong and Esa Davis. confirmedas of 2026-05-20

    13. [13]

      On 17 September 2026 Kennedy named eight new USPSTF members, with pediatric hematologist-oncologist Seth Corey as chair; most are specialists, a departure from the panel's generalist make-up. confirmedas of 2026-09-17

    14. [14]

      A 2026 Nature Medicine analysis estimated that 37.8% of new cancer cases worldwide in 2022 (7.1 million of 18.7 million) were attributable to 30 modifiable risk factors, led by smoking, infections and alcohol; WHO cites it as about 38% of cancers being preventable. confirmedas of 2026-10-11

    15. [15]

      The American Cancer Society's Colorectal cancer statistics, 2026 report says colorectal cancer is the leading cause of cancer death in US adults under 50, with incidence rising 3% a year at ages 20 to 49, and calls for educating clinicians and the public about its symptoms. confirmedas of 2026-10-11

    16. [16]

      The ACS update recommends negative HPV tests at ages 60 and 65 before stopping cervical screening, citing high cervical cancer rates in people over 65. confirmedas of 2026-10-11

    17. [17]

      The American Cancer Society projects about 2,114,850 new cancer cases and 626,140 cancer deaths in the US in 2026, and estimates that falling mortality since 1991 averted 4.8 million deaths, largely through smoking reductions, earlier detection and better treatment. confirmedas of 2026-10-11

      • Cancer statistics, 2026 · CA: A Cancer Journal for Clinicians (American Cancer Society) · 2026-01-01 · Abstract (retrieved 2026-10-11)
      • Cancer statistics, 2026 · CA: A Cancer Journal for Clinicians (American Cancer Society) · 2026-01-01 · Abstract (retrieved 2026-10-11)
    18. [18]

      GRAIL submitted a premarket approval (PMA) application for Galleri to the FDA on 29 January 2026; the FDA had designated Galleri a Breakthrough Device in 2018. confirmedas of 2026-10-11

    19. [19]

      GRAIL's PMA included PATHFINDER 2 initial results and first-round NHS-Galleri performance and safety data, plus a bridging study. confirmedas of 2026-08-06

    20. [20]

      Across NHS-Galleri's three rounds, specificity was 99.50% to 99.60%, positive predictive value fell from 58.0% to 45.8%, and episode sensitivity was 26.7% to 37.2% for all cancers and 47.6% to 63.4% for the 12 prespecified types. confirmedas of 2026-10-11

    21. [21]

      In PATHFINDER 2 (32,007 performance-analysable North American participants aged 50 or older), Galleri's cancer detection rate was 0.54%, positive predictive value 60.3%, specificity 99.64%, and episode sensitivity 39.3% for all cancers and 69.8% for 12 prespecified cancers; it was a single-arm study. confirmedas of 2026-10-11

    22. [22]

      The UK NSC's position (October 2026) is that surrogate outcomes such as fewer late-stage cancers cannot yet replace cancer-specific deaths as the main measure of screening benefit, because finding more early cancers does not necessarily mean fewer deaths. confirmedas of 2026-10-01

    23. [23]

      The USPSTF's current cervical recommendation (August 2018) is cytology every 3 years at ages 21 to 29, and at 30 to 65 cytology every 3 years, high-risk HPV testing alone every 5 years or co-testing every 5 years; an update is in progress. confirmedas of 2026-10-11

    24. [24]

      The USPSTF (May 2018) says PSA screening for men aged 55 to 69 should be an individual decision (grade C) and recommends against it at 70 and older (grade D); an update is in progress. confirmedas of 2026-10-11

    Revision history (1)
    1. Page created with 2026 timeline through 11 October.

    Created Oct 11, 2026. Last reviewed by an editor on Oct 11, 2026. Next scheduled review: Nov 11, 2026.

    Cite this page

    "Cancer screening and prevention tracker: 2026 guidelines, trials, FDA." ContentLora, updated Oct 11, 2026. https://contentlora.com/events/cancer-screening-tracker

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    ☰ Contents